Laurus Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LAURUS, and what generic and branded alternatives to LAURUS drugs are available?
LAURUS has seventeen approved drugs.
There are seven tentative approvals on LAURUS drugs.
Summary for Laurus
US Patents: | 0 |
Tradenames: | 13 |
Ingredients: | 13 |
NDAs: | 17 |
Patent Litigation for Laurus: | See patent lawsuits for Laurus |
Drugs and US Patents for Laurus
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Laurus | PIRFENIDONE | pirfenidone | CAPSULE;ORAL | 212724-001 | Jul 19, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Laurus | OSELTAMIVIR PHOSPHATE | oseltamivir phosphate | CAPSULE;ORAL | 218565-003 | May 1, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Laurus | GABAPENTIN | gabapentin | CAPSULE;ORAL | 217546-003 | May 12, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Laurus | OSELTAMIVIR PHOSPHATE | oseltamivir phosphate | CAPSULE;ORAL | 218565-002 | May 1, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Laurus | ATAZANAVIR SULFATE | atazanavir sulfate | CAPSULE;ORAL | 212579-002 | Apr 30, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Laurus | EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE | efavirenz; lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 213038-001 | May 14, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Laurus | GABAPENTIN | gabapentin | TABLET;ORAL | 217965-001 | Apr 8, 2024 | AB1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.